[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554299":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":26,"locations":32,"responsibleParty":47,"collaborators":25,"id":50,"slug":25,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":25,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":25,"enrollmentInfo":58,"targetDuration":25,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":25,"overallStatus":34,"whyStopped":25,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Gangnam Severance Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"I (Binaural)","EXPERIMENTAL","Binaural sound using earphone will be applied.",[13],"Procedure: Binaural sound",{"label":15,"type":16,"description":17,"interventionNames":18},"II (Placebo)","PLACEBO_COMPARATOR","Only headphone without sound will be applied.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"PROCEDURE","Binaural sound","Binaural sound: Binaural sound will be applied.",[9,15],null,[27],{"name":28,"role":29,"phone":30,"phoneExt":25,"email":31},"Hyun-Chang Kim","CONTACT","0220194601","gsirb@yuhs.ac",[33],{"facility":5,"status":34,"city":35,"state":25,"zip":25,"country":36,"countryCode":25,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","Seoul","South Korea",{"type":38,"coordinates":39},"Point",[40,41],126.9784,37.566,{"lat":41,"lon":40},[44],{"name":45,"role":29,"phone":46,"phoneExt":25,"email":25},"Hyun Chang Kim","82-2-2019-4601",{"type":48,"investigatorFullName":28,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Associate Professor","100554299",false,"NCT06497283","Binaural Sound for Remimazolam Maintenance","The Effect of Intraoperative Binaural Sound on Remifentanil Dose Required for General Anesthesia Using Remimazolam: a Randomized, Placebo-controlled Trial","Inclusion Criteria:\n\n1. Patients scheduled for general anesthesia\n2. Patients aged 20-60\n3. Patients with American Society of Anesthesiologist physical status classification 1-2\n4. Patients with ideal body weight 50-80 kg\n\nExclusion Criteria:\n\n1. Patients with hearing disability\n2. Patients using opioids or sedatives in 1 week\n3. Patients who are dependent for alcoholics or drugs\n4. Patients with hypersensitivities to remimazolam or remifentanil\n5. Patients with arrhythmia, cardiovascular disease, heart failure, or hypovolemia\n6. Patients with liver failure","ALL","20 Years",{"count":59,"type":60},72,"ESTIMATED","INTERVENTIONAL",[63],"NA","It is important to decrease the remifentanil dose for general anesthesia maintenance when using remimazolam. We will evaluate the effect of binaural sound on general anesthesia maintenance with remimazolam infusion.",[66,67,68],"General Anesthesia","Prostate Cancer Stage","Uterine Myoma","2024-08-07",{"date":71,"type":72},"2024-08-09","ACTUAL",{"date":74,"type":72},"2024-07-12",{"date":76,"type":60},"2025-02-28",{"name":5,"class":6},1]